Thanks for emailing that article!
Glaucoma Research Foundation will be hosting Glaucoma 360 New Horizons Forum in San Francisco on February 9, 2018. Now in its 7th year, this unique meeting highlights promising and innovative advances in glaucoma and unites clinicians with leaders in medicine, science, business, finance, and the FDA.
Thomas Brunner, President and CEO of Glaucoma Research Foundation, remarked on the importance of bringing these key individuals together: “Glaucoma 360 fosters critical collaborations with everyone dedicated to novel, new therapies in glaucoma.” He added, “The program includes ample networking time for further discussions and interactions. With 350 to 400 participants at the New Horizons Forum, it is still an intimate meeting with access to key opinion leaders, senior executives and regulatory officials.”
Ike K. Ahmed, MD, will deliver the Drs. Henry and Frederick Sutro Memorial Lecture to kick start a full day of presentations and panel discussions featuring innovations in glaucoma drug delivery, pharmaceuticals, and devices, as well as sessions focusing on working with the FDA and securing venture capital funding. A special session on virtual reality will be included to explore the current and promising use of this technology in ophthalmology.
Showcasing innovative developments from early-stage companies and researchers is another important aspect of the meeting. At the 2017 New Horizons Forum, more than 20 presentations featured new technologies and therapeutic options in glaucoma. Mr. Brunner adds, “This year, we are reviewing close to 100 companies and university start-ups that have novel approaches to glaucoma devices, drug delivery, management and drug therapy. Our Program Committee and session moderators have quite a challenge to choose the top innovations to highlight at our 2018 meeting.”
Along with early-stage companies, industry executives play a major role at the meeting and will discuss their approaches to developing and acquiring inventive products during panel discussions focused on glaucoma drugs and devices.
Glaucoma 360 Program Committee member Richard A. Lewis, MD, notes, “Glaucoma 360 is a wonderful mix of business and medicine focusing on innovation occurring in and around glaucoma. Those of us who care for patients as well as those who provide products for this disease know that innovation is long overdue. There is no better forum anywhere than Glaucoma 360.”
The New Horizons Forum is the centerpiece of Glaucoma 360, which includes the Annual Gala on February 8 honoring Thomas Burns, President and CEO of Glaukos Corporation, and Carl V. Migliazzo, MD. Glaucoma 360 closes on February 10th with the 22nd Annual Glaucoma Symposium CME and the 3rd Annual Optometric Glaucoma Symposium.
To learn more about Glaucoma 360 events from February 8 to 10, 2018 in San Francisco, visit: www.glaucoma360.org.
Last reviewed on December 18, 2017